What happened with PHR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Phreesia helps medical practices, health systems and hospitals manage the steps around a patient’s care, from scheduling and registration to communications and bill payment. These organizations pay for access to its integrated platform, with subscriptions and related services forming its largest revenue category. Phreesia also collects processing fees when patients pay medical bills through its platform. Its AccessOne MedCard business provides patient financing and earns interest and other account charges, along with servicing fees. Together, subscriptions and payment services generate most of its revenue, which comes almost entirely from the United States.
The same healthcare-client network gives Phreesia an audience for Network Solutions. Life sciences companies and other organizations pay to deliver health-related communications to consenting patients, generally under annual contracts priced per engagement. A larger healthcare-client base expands the patients these programs can reach; this business also depends on patients choosing to receive communications and clients’ marketing budgets.
The core business depends on healthcare clients renewing and expanding their use, patients using its payment tools, and continued access to third-party payment processors and electronic medical record integrations. Phreesia has historically received a substantial share of revenue from a limited number of clients. Health privacy laws and client agreements restrict how it may collect, use and disclose patient information, while AccessOne MedCard’s lending is subject to state licensing and consumer-lending rules.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Waystar competes with Phreesia for healthcare providers buying software to check coverage, estimate costs and collect patient payments. Watch Waystar’s new client wins and sales of additional products to existing clients for signs of competition for those providers’ spending.
OptimizeRx competes with Phreesia’s Network Solutions for pharmaceutical marketing budgets: both charge life sciences companies to deliver targeted campaigns to patients and healthcare providers. Watch OptimizeRx’s pharmaceutical campaign business for clues to the spending pool supporting Phreesia’s patient-engagement revenue.
Doximity competes for the drug-brand marketing budgets that also fund Phreesia’s patient and provider engagement campaigns, charging pharmaceutical manufacturers to place sponsored content on its medical professional network. Its pharmaceutical marketing programs, purchased brand by brand, are the business to watch rather than its hiring or workflow products.
Paymentus overlaps with Phreesia in helping healthcare billers present bills and collect patient payments, earning transaction fees for its billing and payment technology. Watch its healthcare billing business specifically: Paymentus also serves many other industries, so its overall results are not a direct measure of demand for Phreesia’s patient-payment offering.
Repay overlaps with Phreesia’s patient-payment processing by helping consumer-healthcare and healthcare organizations accept electronic payments instead of cash or checks. Watch its healthcare customers and payment-system integrations; its broader consumer lending and business-payment operations make total revenue a less direct comparison.
Waystar Holding Corp. earningsWAY
Waystar's report will show whether healthcare providers are still buying and adding to its software, revealing how Phreesia's competing customers are spending.
Look at new client wins alongside sales of additional products to existing clients. Strength in both would show that providers are still spending on tools for coverage checks, cost estimates and patient payments, while also showing Phreesia faces an active rival for that budget. Weakness in both would point to more cautious provider spending, which could make it harder for Phreesia to win clients or expand sales. The takeaway is the strength of demand for these tools, not a substitute for Phreesia's own results.
Paymentus Holdings, Inc. earningsPAY
Paymentus's healthcare billing results will show how electronic patient billing and collection are faring, a market that overlaps with Phreesia's payment business.
Focus on Paymentus's healthcare billing business, not its results across many industries. If that business shows stronger client or transaction activity, it would indicate continued demand for electronic healthcare billing and collection, a channel Phreesia also serves; weakness would point to less momentum in that channel and make Phreesia's patient payment volume worth watching. The takeaway is the direction of demand in healthcare payments, not a like-for-like revenue comparison.
OptimizeRx Corporation earningsOPRX
OptimizeRx's report will show whether life-sciences companies are still funding targeted campaigns to patients and providers, the budgets Phreesia's Network Solutions also pursues.
Focus on OptimizeRx's pharmaceutical campaign business rather than treating its overall results as a direct read of Phreesia's Network Solutions revenue. If campaign activity or related revenue strengthens, life-sciences companies are still funding targeted marketing, but that does not show Phreesia won the same dollars. If it weakens, the pool of budgets both companies pursue may be cooling, leaving less support for Phreesia's patient-engagement revenue. The takeaway is whether this marketing budget pool is active and what that means for Phreesia's competitive setting.
Phreesia, Inc. earningsThis company
Phreesia's report will show whether its healthcare-services clients are growing and whether revenue per client and patient payment volume are growing with them.
Read the number of healthcare-services clients alongside revenue per client and patient payment volume. If all rise, Phreesia is adding clients and earning more as they use the platform; if client numbers rise but revenue per client or payment volume weakens, adding clients is not translating into stronger monetization. Together, these measures show whether growth has support from both a wider client base and deeper use.
